Douglas Lane & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $69.4M | Sell |
|
|||||
|
2025
Q2 | $72.4M | Sell |
|
|||||
|
2025
Q1 | $102M | Sell |
|
|||||
|
2024
Q4 | $97M | Sell |
|
|||||
|
2024
Q3 | $93.1M | Sell |
|
|||||
|
2024
Q2 | $75.3M | Buy |
|
|||||
|
2024
Q1 | $95.9M | Buy |
|
|||||
|
2023
Q4 | $88.5M | Sell |
|
|||||
|
2023
Q3 | $101M | Buy |
|
|||||
|
2023
Q2 | $109M | Sell |
|
|||||
|
2023
Q1 | $119M | Sell |
|
|||||
|
2022
Q4 | $125M | Sell |
|
|||||
|
2022
Q3 | $131M | Sell |
|
|||||
|
2022
Q2 | $145M | Sell |
|
|||||
|
2022
Q1 | $140M | Buy |
|
|||||
|
2021
Q4 | $118M | Buy |
|
|||||
|
2021
Q3 | $108M | Buy |
|
|||||
|
2021
Q2 | $121M | Buy |
|
|||||
|
2021
Q1 | $113M | Buy |
|
|||||
|
2020
Q4 | $110M | Sell |
|
|||||
|
2020
Q3 | $109M | Sell |
|
|||||
|
2020
Q2 | $108M | Sell |
|
|||||
|
2020
Q1 | $107M | Sell |
|
|||||
|
2019
Q4 | $132M | Buy |
|
|||||
|
2019
Q3 | $67.5M | Buy |
|
|||||
|
2019
Q2 | $59.3M | Buy |
|
|||||
|
2019
Q1 | $59.9M | Buy |
|
|||||
|
2018
Q4 | $65.1M | Buy |
|
|||||
|
2018
Q3 | $76M | Buy |
|
|||||
|
2018
Q2 | $65.8M | Buy |
|
|||||
|
2018
Q1 | $61.9M | Buy |
|
|||||
|
2017
Q4 | $56.7M | Buy |
|
|||||
|
2017
Q3 | $55.2M | Buy |
|
|||||
|
2017
Q2 | $39.6M | Buy |
|
|||||
|
2017
Q1 | $28.3M | Buy |
|
|||||
|
2016
Q4 | $22.5M | Buy |
|
|||||
|
2016
Q3 | $20.6M | Sell |
|
|||||
|
2016
Q2 | $29.5M | Sell |
|
|||||
|
2016
Q1 | $25.8M | Buy |
|